{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of November 2023): No"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2718914"],"location":["Canada","Puerto Rico","Belgium","Hong Kong","United States","Italy","France","Australia","Germany","Spain"],"study_start_month":["7"],"keyword":["Magrolimab","Irinotecan","Leucovorin","Fluorouracil","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)","description":"The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).\nThe primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).","dates":{"creation":"2022-07-15"},"accession":"2718914","cross_references":{"ClinicalTrials___gov":["NCT05330429"],"EU Clinical Trials Register":["2022-500177-13"]}}